A Randomised, Double Blind, Parallel Group, Phase II, Multicentre Study to Assess the Efficacy of ZD1839 (Iressa) 250 and 500mg/day in Patients with Advanced Non-Small Cell Lung Cancer who have failed one or two previous Chemotherapy Regimens; at least one having contained Platinum.

Study identifier:1839IL/0016

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Double Blind, Parallel Group, Phase II, Multicentre Study to Assess the Efficacy of ZD1839 (Iressa) 250 and 500mg/day in Patients with Advanced Non-Small Cell Lung Cancer who have failed one or two previous Chemotherapy Regimens; at least one having contained Platinum.

Medical condition

lung cancer

Phase

Phase 2

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Oct 2000

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2025 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

"There is no result for the study"

Documents available

CSR-1839IL-0016.pdf
Download
Trial Results Summaries
Available here

A Randomised, Double Blind, Parallel Group, Phase II, Multicentre Study to Assess the Efficacy of ZD1839 (Iressa) 250 and 500mg/day in Patients with Advanced Non-Small Cell Lung Cancer who have failed one or two previous Chemotherapy Regimens; at least one having contained Platinum.

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

CSR-1839IL-0016.pdf

Trial Results Summaries